Karsanbhai Surendralal Lanca Buys Shares of Merck & Co., Inc.

Karsanbhai Surendralal Lanca made a notable move by purchasing 127 shares of Merck & Co., Inc. on June 30, 2026. The shares were bought at an average price of $128.50 each, bringing the total transaction to $16,319.50. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Merck & Co., Inc.

On June 30, 2026, several insiders of Merck & Co., Inc. made purchases. Karsanbhai Surendralal Lanca acquired 127 shares at $128.50 each. Mary Ellen Coe also bought 234 shares on the same day at the same price, while Christine Seidman purchased 63 shares. Earlier in May, Kathy Warden and Paul Rothman each bought 1,853 shares at a price of $118.72.

Other Institutional Activity in Merck & Co., Inc.

Among Merck's institutional investors, BlackRock, Inc. increased its holdings by 6,734,865 shares, ending with 225,830,330 shares valued at approximately $27.17 billion, marking a 3.1% increase. Vanguard Capital Management LLC opened a new position with 160,987,624 shares worth about $19.37 billion. Meanwhile, State Street Corp reduced its stake by 714,495 shares to a total of 119,325,673 shares, valued at $14.45 billion, representing a 0.6% decrease. Wellington Management Group LLP also trimmed its holdings by 2,120,487 shares, leaving it with 84,314,971 shares valued at $10.14 billion, a 2.5% reduction.

Merck & Co., Inc. Stock Down 13.4%

Shares of NYSE:MRK traded near $128.50 on Wednesday. Merck & Co., Inc. boasts a market capitalization of $317.37 billion, with a P/E ratio of 36.20 and a forward P/E of 13.42. The stock has shown a 52-week range between $76.66 and $130.29. Merck's 50-day moving average stands at $116.12, while the 200-day moving average is $106.56. The company maintains a current ratio of 1.30 and a quick ratio of 0.70, with a debt-to-equity ratio of 106.94.

Recent Earnings

Merck & Co., Inc. reported revenues of approximately $65.77 billion, with a growth rate of 4.9%. The company's earnings per share (EPS) is $3.55, and it has a net profit margin of 13.6%. Return on equity (ROE) is strong at 18.9%. The next earnings report is scheduled for August 4, 2026.

Dividend

Merck & Co., Inc. offers an annual dividend rate of $3.40, yielding 2.65%. The dividend payout ratio is 93.52%.

Analysts Set New Price Targets

On June 30, 2026, B of A Securities maintained its buy rating on Merck with a price target of $141. Scotiabank also upheld a buy rating with a higher target of $155. On June 24, 2026, CICC initiated coverage with a buy rating and a target of $138. Consensus among 28 analysts is a buy rating, with an average price target of $130.39.

About Merck & Co., Inc.

Merck & Co., Inc., headquartered in Rahway, New Jersey, is a global healthcare company. It develops and sells a wide range of pharmaceuticals for human and animal health. The company's products cover various therapeutic areas, including cancer, vaccines, and infectious diseases. Merck collaborates with other firms such as Daiichi Sankyo and AstraZeneca to enhance its drug offerings. Led by CEO Robert M. Davis, the company employs about 73,000 people worldwide.

Bottom Line

Karsanbhai Surendralal Lanca's recent purchase of Merck shares highlights insider confidence in the company. Investors often watch insider transactions closely as they can signal management's perspective on the company's future. Merck's strong financials and positive analyst ratings suggest continued interest in its stock. However, as with all 13F filings and insider reports, these transactions reflect past actions and may not indicate current positions.